Mide Hastalıklarında Helikobakter Pilori ve Rolü
Özet
Helikobakter pilori (H. pilori), dünya nüfusunun büyük bir kısmını etkileyen, mide ortamına yüksek uyum sağlamış spiral şekilli gram-negatif bir bakteridir. Erken yaşam dönemindeki sosyoekonomik yetersizlikler ve kalabalık yaşam koşulları bulaşma riskini artırırken; fekal-oral veya oral-oral yollarla kişiden kişiye yayılmaktadır. Bakteri, salgıladığı üreaz, katalaz ve fosfolipaz gibi enzimler ve VacA ile CagA gibi virülans faktörleri sayesinde mide mukozal bariyerini bozarak doku hasarına ve kronik inflamasyona yol açar. H. pilori enfeksiyonu çoğunlukla asemptomatik seyretse de tedavi edilmediğinde akut ve kronik gastrit, peptik ülser, demir eksikliği anemisi ve B12 vitamini eksikliği gibi sistemik sorunlara neden olabilir. Ayrıca, mide mukozasındaki sürekli bağışıklık uyarımı ve hücresel hasar; intestinal metaplazi, gastrik atrofi, mide lenfoması (MALToma) ve mide kanseri gelişimi ile güçlü bir şekilde ilişkilidir. Tanısında histoloji ve hızlı üreaz testi gibi invaziv yöntemlerin yanı sıra üre nefes testi ve dışkı antijen testi gibi non-invaziv aktif enfeksiyon testleri kullanılır. Tedavisi, antibiyotik direncine göre şekillenen proton pompa inhibitörleri ve çoklu antibiyotik kombinasyonlarından oluşan 14 günlük rejimleri içerir ve eradikasyon başarısı tedavi sonrası testlerle mutlaka doğrulanmalıdır.
Helicobacter pylori (H. pylori) is a highly adapted, spiral-shaped, gram-negative bacterium that infects a significant portion of the global population, causing chronic inflammatory disorders. Transmission primarily occurs from person to person through fecal-oral or oral-oral routes, with risk factors closely tied to low socioeconomic status and crowded living conditions during early childhood. The bacterium colonizes the gastric mucosa and induces tissue damage through key enzymes like urease, catalase, and phospholipase, alongside virulence factors such as VacA and CagA cytokines. While most infected individuals remain asymptomatic, untreated chronic inflammation can lead to acute or chronic gastritis, peptic ulcer disease, and extra-gastrointestinal manifestations including iron deficiency anemia and vitamin B12 malabsorption. Furthermore, persistent immune stimulation and DNA damage significantly elevate the risk of gastric atrophy, intestinal metaplasia, MALT lymphoma, and gastric adenocarcinoma. Diagnosis relies on invasive endoscopic methods like histology and rapid urease tests, or non-invasive active infection assays such as the urea breath test and stool antigen test. Eradication therapies involve 14-day multi-antimicrobial regimens combined with proton pump inhibitors, tailored to antibiotic resistance profiles, and treatment success must always be confirmed post-therapy.
Referanslar
Goodwin CS, Worsley BW. Microbiology of Helicobacter pilori. Gastroenterol Clin North Am 1993; 22:5.
Cave DR. Transmission and epidemiology of Helicobacter pilori. Am J Med 1996; 100:12S.
Pounder RE, Ng D. The prevalence of Helicobacter pilori infection in different countries. Aliment Pharmacol Ther 1995; 9 Suppl 2:33.
Tsugane S, Tei Y, Takahashi T, et al. Salty food intake and risk of Helicobacter pilori infection. Jpn J Cancer Res 1994; 85:474.
Fox JG, Dangler CA, Taylor NS, et al. High-salt diet induces gastric epithelial hyperplasia and parietal cell loss, and enhances Helicobacter pilori colonization in C57BL/6 mice. Cancer Res 1999; 59:4823.
Lee SA, Kang D, Shim KN, et al. Effect of diet and Helicobacter pilori infection to the risk of early gastric cancer. J Epidemiol 2003; 13:162.
Machida-Montani A, Sasazuki S, Inoue M, et al. Association of Helicobacter pilori infection and environmental factors in non-cardia gastric cancer in Japan. Gastric Cancer 2004; 7:46.
Graham DY, Malaty HM, Evans DG, et al. Epidemiology of Helicobacter pilori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology 1991; 100:1495.
Perry S, de la Luz Sanchez M, Yang S, et al. Gastroenteritis and transmission of Helicobacter pilori infection in households. Emerg Infect Dis 2006; 12:1701.
Mégraud F. Transmission of Helicobacter pilori: faecal-oral versus oral-oral route. Aliment Pharmacol Ther 1995; 9 Suppl 2:85.
Borody TJ, Andrews P, Mancuso N, et al. Helicobacter pilori reinfection rate, in patients with cured duodenal ulcer. Am J Gastroenterol 1994; 89:529.
Archimandritis A, Balatsos V, Delis V, et al. "Reappearance" of Helicobacter pilori after eradication: implications on duodenal ulcer recurrence: a prospective 6 year study. J Clin Gastroenterol 1999; 28:345.
Suerbaum S, Michetti P. Helicobacter pilori infection. N Engl J Med 2002; 347:1175.
Ernst PB, Peura DA, Crowe SE. The translation of Helicobacter pilori basic research to patient care. Gastroenterology 2006; 130:188.
Hu LT, Mobley HL. Purification and N-terminal analysis of urease from Helicobacter pilori. Infect Immun 1990; 58:992.
Mobley HL. The role of Helicobacter pilori urease in the pathogenesis of gastritis and peptic ulceration. Aliment Pharmacol Ther 1996; 10 Suppl 1:57.
Nilius M, Malfertheiner P. Helicobacter pilori enzymes. Aliment Pharmacol Ther 1996; 10 Suppl 1:65.
Slomiany BL, Kasinathan C, Slomiany A. Lipolytic activity of Campylobacter pilori: effect of colloidal bismuth subcitrate (De-Nol). Am J Gastroenterol 1989; 84:1273.
Hazell SL. Urease and catalase as virulence factors of Helicobacter pilori. In: Helicobacter pilori 1990, Menge H, Gregor M, Tytgat GN, et al (Eds), Springer Verlag, Berlin 1991
Mobley HL. Defining Helicobacter pilori as a pathogen: strain heterogeneity and virulence. Am J Med 1996; 100:2S.
Tombola F, Morbiato L, Del Giudice G, et al. The Helicobacter pilori VacA toxin is a urea permease that promotes urea diffusion across epithelia. J Clin Invest 2001; 108:929.
Fujikawa A, Shirasaka D, Yamamoto S, et al. Mice deficient in protein tyrosine phosphatase receptor type Z are resistant to gastric ulcer induction by VacA of Helicobacter pilori. Nat Genet 2003; 33:375.
Letley DP, Rhead JL, Twells RJ, et al. Determinants of non-toxicity in the gastric pathogen Helicobacter pilori. J Biol Chem 2003; 278:26734.
Covacci A, Censini S, Bugnoli M, et al. Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pilori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci U S A 1993; 90:5791.
Blaser MJ. Role of vacA and the cagA locus of Helicobacter pilori in human disease. Aliment Pharmacol Ther 1996; 10 Suppl 1:73.
Figura N. Helicobacter pilori exotoxins and gastroduodenal diseases associated with cytotoxic strain infection. Aliment Pharmacol Ther 1996; 10 Suppl 1:79.
Spechler SJ, Fischbach L, Feldman M. Clinical aspects of genetic variability in Helicobacter pilori. JAMA 2000; 283:1264.
Weel JF, van der Hulst RW, Gerrits Y, et al. The interrelationship between cytotoxin-associated gene A, vacuolating cytotoxin, and Helicobacter pilori-related diseases. J Infect Dis 1996; 173:1171.
Huang JQ, Zheng GF, Sumanac K, et al. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology 2003; 125:1636.
van Doorn LJ, Figueiredo C, Sanna R, et al. Clinical relevance of the cagA, vacA, and iceA status of Helicobacter pilori. Gastroenterology 1998; 115:58.
Atherton JC, Cao P, Peek RM Jr, et al. Mosaicism in vacuolating cytotoxin alleles of Helicobacter pilori. Association of specific vacA types with cytotoxin production and peptic ulceration. J Biol Chem 1995; 270:17771.
Atherton JC, Peek RM Jr, Tham KT, et al. Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of Helicobacter pilori. Gastroenterology 1997; 112:92.
Peek RM Jr, Thompson SA, Donahue JP, et al. Adherence to gastric epithelial cells induces expression of a Helicobacter pilori gene, iceA, that is associated with clinical outcome. Proc Assoc Am Physicians 1998; 110:531.
Nogueira C, Figueiredo C, Carneiro F, et al. Helicobacter pilori genotypes may determine gastric histopathology. Am J Pathol 2001; 158:647.
Gerhard M, Lehn N, Neumayer N, et al. Clinical relevance of the Helicobacter pilori gene for blood-group antigen-binding adhesin. Proc Natl Acad Sci U S A 1999; 96:12778.
Yamaoka Y, Kikuchi S, el-Zimaity HM, et al. Importance of Helicobacter pilori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production. Gastroenterology 2002; 123:414.
Mitchell HM, Hazell SL, Kolesnikow T, et al. Antigen recognition during progression from acute to chronic infection with a cagA-positive strain of Helicobacter pilori. Infect Immun 1996; 64:1166.
Kosunen TU. Antibody titres in Helicobacter pilori infection: implications in the follow-up of antimicrobial therapy. Ann Med 1995; 27:605.
Cover TL, Glupczynski Y, Lage AP, et al. Serologic detection of infection with cagA+ Helicobacter pilori strains. J Clin Microbiol 1995; 33:1496.
Crabtree JE. Eradication of chronic Helicobacter pilori infection by therapeutic vaccination. Gut 1998; 43:7.
Zeng M, Mao XH, Li JX, et al. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pilori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 386:1457.
Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20:1161.
Carpenter HA, Talley NJ. Gastroscopy is incomplete without biopsy: clinical relevance of distinguishing gastropathy from gastritis. Gastroenterology 1995; 108:917.
Odze RD, Goldblum JR. Inflammatory disorders of the stomach. In: Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas, Lash RH, Lauwers GY, et al (Eds), Saunders, Philadelphia 2009. p.285.
Hazell SL, Lee A, Brady L, Hennessy W. Campylobacter piloridis and gastritis: association with intercellular spaces and adaptation to an environment of mucus as important factors in colonization of the gastric epithelium. J Infect Dis 1986; 153:658.
Väänänen H, Vauhkonen M, Helske T, et al. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol 2003; 15:885.
Elitsur Y, Raghuverra A, Sadat T, Vaid P. Is gastric nodularity a sign for gastric inflammation associated with Helicobacter pilori infection in children? J Clin Gastroenterol 2000; 30:286.
Glickman JN, Antonioli DA. Gastritis. Gastrointest Endosc Clin N Am 2001; 11:717.
Iacobuzio-Donahue CA, Montgomery E, Goldblum JR. Non-neoplastic disorders of the stomach. In: Gastrointestinal and Liver Pathology, Bhattacharya B (Ed), Churchill Livingstone Elsevier, Philadelphia 2005. p.72.
Yuan W, Li Yumin, Yang Kehu, et al. Iron deficiency anemia in Helicobacter pilori infection: meta-analysis of randomized controlled trials. Scand J Gastroenterol 2010; 45:665.
Tsay FW, Hsu PI. H. pilori infection and extra-gastroduodenal diseases. J Biomed Sci 2018; 25:65.
Mwafy SN, Afana WM. Hematological parameters, serum iron and vitamin B12 levels in hospitalized Palestinian adult patients infected with Helicobacter pilori: a case-control study. Hematol Transfus Cell Ther 2018; 40:160.
Lanas A, Remacha B, Sáinz R, Hirschowitz BI. Study of outcome after targeted intervention for peptic ulcer resistant to acid suppression therapy. Am J Gastroenterol 2000; 95:513.
Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.
El-Omar EM, Rabkin CS, Gammon MD, et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003; 124:1193.
Ding SZ, Minohara Y, Fan XJ, et al. Helicobacter pilori infection induces oxidative stress and programmed cell death in human gastric epithelial cells. Infect Immun 2007; 75:4030
Moss SF, Calam J, Agarwal B, et al. Induction of gastric epithelial apoptosis by Helicobacter pilori. Gut 1996; 38:498.
Jones NL, Shannon PT, Cutz E, et al. Increase in proliferation and apoptosis of gastric epithelial cells early in the natural history of Helicobacter pilori infection. Am J Pathol 1997; 151:1695.
Tsugane S, Tei Y, Takahashi T, et al. Salty food intake and risk of Helicobacter pilori infection. Jpn J Cancer Res 1994; 85:474.
Fox JG, Dangler CA, Taylor NS, et al. High-salt diet induces gastric epithelial hyperplasia and parietal cell loss, and enhances Helicobacter pilori colonization in C57BL/6 mice. Cancer Res 1999; 59:4823.
Lee SA, Kang D, Shim KN, et al. Effect of diet and Helicobacter pilori infection to the risk of early gastric cancer. J Epidemiol 2003; 13:162.
Machida-Montani A, Sasazuki S, Inoue M, et al. Association of Helicobacter pilori infection and environmental factors in non-cardia gastric cancer in Japan. Gastric Cancer 2004; 7:46.
You WC, Zhang L, Gail MH, et al. Gastric dysplasia and gastric cancer: Helicobacter pilori, serum vitamin C, and other risk factors. J Natl Cancer Inst 2000; 92:1607.
Block G. Vitamin C and cancer prevention: the epidemiologic evidence. Am J Clin Nutr 1991; 53:270S.
Feiz HR, Mobarhan S. Does vitamin C intake slow the progression of gastric cancer in Helicobacter pilori-infected populations? Nutr Rev 2002; 60:34.
Cho Y, Lee DH, Oh HS, et al. Higher prevalence of obesity in gastric cardia adenocarcinoma compared to gastric non-cardia adenocarcinoma. Dig Dis Sci 2012; 57:2687.
Yang P, Zhou Y, Chen B, et al. Overweight, obesity and gastric cancer risk: results from a meta-analysis of cohort studies. Eur J Cancer 2009; 45:2867.
Lee YC, Chiang TH, Chou CK, et al. Association Between Helicobacter pilori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. Gastroenterology 2016; 150:1113.
Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer 1972; 29:252.
Clark EA, Ledbetter JA. How B and T cells talk to each other. Nature 1994; 367:425.
Eck M, Schmausser B, Haas R, et al. MALT-type lymphoma of the stomach is associated with Helicobacter pilori strains expressing the CagA protein. Gastroenterology 1997; 112:1482.
Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pilori. Lancet 1993; 342:575.
Laine L, Lewin D, Naritoku W, et al. Prospective comparison of commercially available rapid urease tests for the diagnosis of Helicobacter pilori. Gastrointest Endosc 1996; 44:523.
Gatta L, Vakil N, Ricci C, et al. Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and stool test for Helicobacter pilori infection. Am J Gastroenterol 2004; 99:823.
Weston AP, Campbell DR, Hassanein RS, et al. Prospective, multivariate evaluation of CLOtest performance. Am J Gastroenterol 1997; 92:1310.
Wright CL, Kelly JK. The use of routine special stains for upper gastrointestinal biopsies. Am J Surg Pathol 2006; 30:357.
Leide-Svegborn S, Stenström K, Olofsson M, et al. Biokinetics and radiation doses for carbon-14 urea in adults and children undergoing the Helicobacter pilori breath test. Eur J Nucl Med 1999; 26:573.
Howden CW, Hunt RH. Guidelines for the management of Helicobacter pilori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998; 93:2330
Laine L, Estrada R, Trujillo M, et al. Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pilori. Ann Intern Med 1998; 129:547.
Vakil N, Rhew D, Soll A, Ofman JJ. The cost-effectiveness of diagnostic testing strategies for Helicobacter pilori. Am J Gastroenterol 2000; 95:1691.
Trevisani L, Sartori S, Galvani F, et al. Evaluation of a new enzyme immunoassay for detecting Helicobacter pilori in feces: a prospective pilot study. Am J Gastroenterol 1999; 94:1830.
Lin HJ, Lo WC, Perng CL, et al. Helicobacter pilori stool antigen test in patients with bleeding peptic ulcers. Helicobacter 2004; 9:663.
Gisbert JP, Trapero M, Calvet X, et al. Evaluation of three different tests for the detection of stool antigens to diagnose Helicobacter pilori infection in patients with upper gastrointestinal bleeding. Aliment Pharmacol Ther 2004; 19:923.
Chey WD, Wong BC, Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pilori infection. Am J Gastroenterol 2007; 102:1808.
Cutler AF, Toskes P. Comparison of [13C]urea blood test to [13C]urea breath test for the diagnosis of Helicobacter pilori. Am J Gastroenterol 1999; 94:959.
Ahmed F, Murthy UK, Chey WD, et al. Evaluation of the Ez-HBT Helicobacter blood test to establish Helicobacter pilori eradication. Aliment Pharmacol Ther 2005; 22:875.
Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pilori infection--the Maastricht IV/ Florence Consensus Report. Gut 2012; 61:646.
Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pilori Infection. Am J Gastroenterol 2017; 112:212.
Cutler AF, Prasad VM, Santogade P. Four-year trends in Helicobacter pilori IgG serology following successful eradication. Am J Med 1998; 105:18.
Crowe SE. Helicobacter pilori Infection. N Engl J Med 2019; 380:1158.
Qasim A, Sebastian S, Thornton O, et al. Rifabutin- and furazolidone-based Helicobacter pilori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther 2005; 21:91.
Fischbach LA, van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pilori quadruple therapies. Aliment Pharmacol Ther 2004; 20:1071.
Gatta L, Zullo A, Perna F, et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther 2005; 22:45.
Gisbert JP, Gonzalez L, Calvet X. Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pilori eradication. Helicobacter 2005; 10:157.
Graham DY, Hammoud F, El-Zimaity HM, et al. Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pilori eradication. Aliment Pharmacol Ther 2003; 17:1229.
Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pilori Infection. Am J Gastroenterol 2017; 112:212.
Fallone CA, Chiba N, van Zanten SV, et al. The Toronto Consensus for the Treatment of Helicobacter pilori Infection in Adults. Gastroenterology 2016; 151:51.
Chey WD, Wong BC, Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pilori infection. Am J Gastroenterol 2007; 102:1808.
Shah SC, Iyer PG, Moss SF. AGA Clinical Practice Update on the Management of Refractory Helicobacter pilori Infection: Expert Review. Gastroenterology 2021; 160:1831.
van der Hulst RW, Keller JJ, Rauws EA, Tytgat GN. Treatment of Helicobacter pilori infection: a review of the world literature. Helicobacter 1996; 1:6.
De Francesco V, Margiotta M, Zullo A, et al. Clarithromycin-resistant genotypes and eradication of Helicobacter pilori. Ann Intern Med 2006; 144:94.
McMahon BJ, Hennessy TW, Bensler JM, et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pilori infections. Ann Intern Med 2003; 139:463.
Shah SC, Iyer PG, Moss SF. AGA Clinical Practice Update on the Management of Refractory Helicobacter pilori Infection: Expert Review. Gastroenterology 2021; 160:1831.
Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology 2006; 131:283.
